Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Patients With Pheochromocytoma and Paraganglioma
Description:
This study will enroll up to 30 evaluable patients with pheochromocytoma or paraganglioma who are undergoing surgical or systemic treatment. A pre-treatment 18F-FluorThanatrace ([18F]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy. PET/CT imaging will be used to evaluate PARP-1 expression in sites of pheochromocytoma or paraganglioma using the investigational radiotracer [18F]FTT. This is an observational study in that [18F]FTT PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the [18F]FTT PET/CT results, treatment decisions will be made by the treating physicians based upon clinical criteria.
Sponsor:
Heather Wachtel
Contacts:
Heather Wachtel, MD (Principal Investigator)heather.wachtel@pennmedicine.upenn.edu
215-662-2341
Julia T Lewandowskijulia.lewandowski@pennmedicine.upenn.edu
215-662-2961
Government Study Link:
NCT05636540 - Click here to see study onClinicalTrials.gov
